Ching has over 30 years' experience in
healthcare and investment industries. He worked as a Vice President and General
Manager of GE Healthcare in China and was responsible for CT, MR, digital
X-ray, nuclearmedicine, molecular imaging and cardiovascular imaging products,
etc. He also acquired extensive investment experience when he was working at
Siguler Guff, Asia Tech VC, and Booz&Company (Chicago). Ching holds an M.S.E
degree in Biomedical Enigineering from Johns Hopkins University, and an M.B.A
with honors from Univerisity of Chicago.
Larissa has 20+ years’ experience in
management in healthcare industry. Prior to joining CD Capital, she was the General
Manager of Health Science at UL China. She also held several leadership
positions at J&J Medical and GE Healthcare China.
Larissa received her B.S.
from Tongji University and Diploma in management from CEIBS. She is a certified GE Six Sigma Black Belt.
Yongqiu is a well-known entrepreneur and investor. He has established many successful
companies in real estate and manufacturing since 1990s,
and he has engaged in equity investment business for many years.
Ruilin has 20+ years' experience in
management in healthcare industry. Prior to joining CD Capital, Ruilin was the
Vice President and General Manager of Commercial Operations for Greater China
at Illumina. He also held several leadership positions at Thermo Fisher,
including China head of Corporate Marketing and Commercial Operations. Prior to
Thermo Fisher, Ruilin held roles as Vice President of Finance at OrbusNeich and
Vice President of Business Development at Microport Medical (Group) Co.
Ruilin received his doctorate in medical engineering and medical physics from
the Harvard-MIT Division of Health Sciences and Technology, MBA from the Wharton School at the University of
Pennsylvania, master in electrical engineering and computer science from
Massachusetts Institute of Technology, and bachelor in biomedical
engineering from Xi'an Jiaotong University.
Tianji is the managing director at CD
Capital. Prior to joining CD Capital, he
was a Consultant at Accenture. Beside that, he had his own entrepreneurial
experience and hence had profound knowledge on products, business model, and
operation for start-ups. After joining CD Capital, he led investments in
Fussen, MasterVision, Genecast, Soonsolid, and Huigene, etc.
He received his B.A. from Fudan University
and M.A. from University of St Andrews.
Chloe has 10+ years' experience in fund
management and investment. Prior to joining CD Capital, she was a Senior
Investment Manager at Gopher Asset
Management and Senior Product Manager at Noah Private Wealth Management
(NYSE:NOAH). Chloe received her B.A. from Fudan University and her MBA
Ji has 5 years’ experience in investment
and research in healthcare industry. Prior to joining CD Capital , he was an
Investment Manager at GIG. He also had been responsible for patent
research and project management at Shanghai Institute of Meteria Medica,
Chinese Academy of Science. Ji received his B.S. from Xi'an Jiaotong
University and his M.S. from Shanghai Institute of Meteria Medica.
Guanhua has 8 years' experience in
investment and research in healthcare industry. Prior to joining CD Capital, he was an Investment Manager at CASSATR. He also had been responsible for
Ultrasound and MR device development at GE and Mindray. Guanhua received his
B.S. and M.S. from Xi'an Jiaotong
Senior Investment Manager
Senior Investment Manager
Dr.Yiyuan Fang, is a senior investment
manager at CD Capital. Fang is mainly responsible for investment in IVD and
biotech companies. Prior to joining CD Capital, Fang was a Ph.D student in
Institut Pasteur of Shanghai, focusing on immunology research for many
Fang holds a B.S. degree from Zhejiang University and a Ph.D degree from
Chinese Academy of Sciences.
Yiran Cui is an investment associate at CD
Capital. She came to the current role from IQVIA, where she worked in
Management Consulting Department on strategic planning for innovative medical
devices and IVD products.
Yiran was educated at Zhejiang University and
Melbourne University, from which she received a Master’s degree in Biomedical
Dr. Minjun Wang is currently an investment associate at CD Capital, with focus on investment opportunities in innovative biotech and
biomedical technology platforms. He served as a senior medical advisor in
AstraZeneca, and has rich experience in drug discovery and pharmacological
& clinical evaluation.
Dr. Minjun Wang received his bachelor's
degree in pharmacy and PhD in pharmacology from Fudan University.
Dr. Weijin Xu is currently serving as an
investment associate at CD Capital. He has multiple years of research
experience in molecular biology. Prior to CD Capital, Dr. Xu was serving as a
research scientist at Flagship Labs 63 Inc., a Flagship Pioneering funded up-start.
He is currently responsible for investment in novel therapeutics and biotech
Weijin Xu holds a B.S. degree from Fudan
University and a Ph.D. degree in molecular biology from Brandeis University
(Ph.D. Advisor: Dr. Michael Rosbash).
Mr. Zheng is a Senior Analyst at CD Capital
with comprehensive experience in consulting and BD projects. Prior to joining CD Capital,
he worked as a BD manager in Vela Diagnostics Group, mainly focusing on
cooperation with pharma and product launch. Before that, he was a consultant in
IQVIA consulting team mainly focused on antineoplastic drugs and IVD.
Mr. Zheng received a Master of Science in
Molecular Medicine from Imperial College London and Bachelor of Science in
Biochemistry from Liverpool University.
Ms. Chang Su is currently an analyst at CD
Capital. Prior to joining CD Capital, she worked for GE Healthcare as an R&D
Chang Su graduated from Tsinghua
University, with a bachelor degree and a master degree in biomedical